Quick Overview: Further considerations for selecting lenvatinib, sorafenib, or Y-90 are provided in the context of Richard S. Finn, MD, Robin K. (“Katie”) Kelley, MD, and Laura M. Kulik, MD, discuss Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, describes current areas of unmet need in ...
Frontline Therapy For Hcc Optimizing - Detailed Overview & Context
Further considerations for selecting lenvatinib, sorafenib, or Y-90 are provided in the context of Richard S. Finn, MD, Robin K. (“Katie”) Kelley, MD, and Laura M. Kulik, MD, discuss Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Republic of Korea, describes current areas of unmet need in ... Michael A. Morse, MD, FACP, discusses how the specific goals of a patient are factors in determining the appropriate David J. Pinato, MD, PhD, clinical senior lecturer in medical oncology, clinician scientist, consultant medical oncologist, ... Panelists Richard S. Finn, MD, and Arndt Vogel, MD, PhD, discuss the management of side effects with sorafenib in
Laura W. Goff, MD, Vanderbilt-Ingram Cancer Center, shares how she chooses between atezolizumab plus bevacizumab and ... Madappa Kundranda, MD, PhD, a medical oncologist at Banner MD Anderson Cancer Center, discusses the A review of the phase 3 IMbrave150 trial comparing atezolizumab-bevacizumab vs standard of care, sorafenib, as initial A discussion on initiating systemic vs locoregional Anthony B. El-Khoueiry, MD, discusses the A review of factors determining eligibility for resection or transplant and determining
Oliver Waidmann, MD, and Arndt Vogel, MD, discuss how the systemic Panelists Richard S. Finn, MD; Richard H. Marshall, MD; and Jordi Bruix, MD; review recent clinical evidence with
